White spots in pharmaceutical pipelines-EMA identifies potential areas of unmet medical needs.

about

Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.

P2860

Q36088877-A52BE31B-896A-426E-A8DC-0901F31B8532 Q48054105-9DD06E6C-975D-40A6-81DC-B611555183D6

P2860

White spots in pharmaceutical pipelines-EMA identifies potential areas of unmet medical needs.

Item

http://www.wikidata.org/entity/Q38386799

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

White spots in pharmaceutical ...... areas of unmet medical needs.

@en

type

Item

label

White spots in pharmaceutical ...... areas of unmet medical needs.

@en

prefLabel

White spots in pharmaceutical ...... areas of unmet medical needs.

@en

P1476

White spots in pharmaceutical ...... areas of unmet medical needs.

@en

P2093

Agnès Saint-Raymond

http://www.w3.org/2001/XMLSchema#string

Enrico Tognana

http://www.w3.org/2001/XMLSchema#string

Falk Ehmann

http://www.w3.org/2001/XMLSchema#string

Marisa Papaluca

http://www.w3.org/2001/XMLSchema#string

Martina Greco

http://www.w3.org/2001/XMLSchema#string

P2860

Development of and access to products for neglected diseases

The key role of genomics in modern vaccine and drug design for emerging infectious diseases

Association between randomised trial evidence and global burden of disease: cross sectional study (Epidemiological Study of Randomized Trials--ESORT)

RNA virus reverse genetics and vaccine design.

Diagnosing the decline in pharmaceutical R&D efficiency.

Pharmaceutical R&D in the spotlight: why is there still unmet medical need?

Revitalizing psychiatric therapeutics.

Differential pricing of new pharmaceuticals in lower income European countries.

Challenges with advanced therapy medicinal products and how to meet them.

European regulation on orphan medicinal products: 10 years of experience and future perspectives.

P304

353-360

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17512433.2015.1028918

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25797498

http://www.w3.org/2001/XMLSchema#string

White spots in pharmaceutical pipelines-EMA identifies potential areas of unmet medical needs.

about

P2860

P2860

White spots in pharmaceutical pipelines-EMA identifies potential areas of unmet medical needs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698